All Articles

Strategic alliance combines resources to develop treatment option for dry eye syndrome

BRIM Biotechnology Inc. has entered into a new strategic partnership with Ora Inc. for the late-stage clinical development of lead drug candidate BRM421 for dry eye syndrome (DES).

The missing link in the recognition of corneal abnormalities

Polarisation-sensitive optical coherence tomography has facilitated early diagnosis of disease before it becomes apparent on topography.

Making strides in ophthalmology with modern gene therapy techniques

Promising gene therapies in development are pinpointing steps in the pathogenic cascades involved in ocular diseases, such as VEGF for wet AMD and CFI for dry AMD.

Positive topline data from Saturn-2 Phase 3 trial encourages Tarsus to file NDA in 2022

May 08, 2022

TP-03 met the primary and all secondary endpoints, effectively resolved Demodex blepharitis and was well-tolerated with no serious treatment-related adverse events. 56% of patients on TP-03 achieved the primary endpoint of complete collarette cure.

Nanoemulsion formulation enhances IOP reduction, study finds

May 07, 2022

In research sponsored by Skye Bioscience Inc., investigators at the University of Mississippi have demonstrated stronger and longer-lasting reduction of intraocular pressure when a proprietary molecule, SBI-100, is formulated as a nanoemulsion containing the mucoadhesive agent Carbopol 940.